G01N 2333/90209
Acting on nadh or nadph
Official title: acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
G01N2333/90209 (Acting on nadh or nadph) appears on 81 US grants and 141 published applications in this corpus.
Search patents in G01N- Granted patents
- 81
- Published applications
- 141
- Assignees
- 80
- Inventors
- 263
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 3 |
| 2003 | 1 | 5 |
| 2004 | 2 | 4 |
| 2005 | 1 | 4 |
| 2006 | 0 | 5 |
| 2007 | 4 | 7 |
| 2008 | 0 | 4 |
| 2009 | 3 | 5 |
| 2010 | 2 | 6 |
| 2011 | 2 | 7 |
| 2012 | 2 | 10 |
| 2013 | 3 | 3 |
| 2014 | 4 | 8 |
| 2015 | 5 | 6 |
| 2016 | 2 | 6 |
| 2017 | 8 | 13 |
| 2018 | 6 | 8 |
| 2019 | 4 | 5 |
| 2020 | 7 | 9 |
| 2021 | 7 | 4 |
| 2022 | 4 | 4 |
| 2023 | 1 | 3 |
| 2024 | 5 | 3 |
| 2025 | 1 | 5 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biomarkers predictive of cancer cell response to ML329 or a derivative thereof24 Feb 2026US 12,560,609 B2Dana-Farber Cancer Institute, Inc.
- Biomarker for predicting the prognosis of colorectal cancer10 Feb 2026US 12,545,962 B2Gil Medical Center
- Monoclonal antibody specifically binding to thioredoxin 1 and methods of use thereof for breast cancer diagnosis3 Feb 2026US 12,540,941 B2E&S Healthcare Co., Ltd.
- Monoclonal antibody specifically binding to thioredoxin 1 and methods of use thereof for breast cancer diagnosis3 Feb 2026US 12,540,942 B2E&S Healthcare Co., Ltd.
- Methods for measuring Renalase25 Feb 2025US 12,234,500 B2Yale University
- Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (poc) diagnostic testing point-of-care (poc) measurement of absolute neutrophil function (anf)14 May 2026US 2026/0133184 A1Binary, LLC
- Frozen Biofluids Mitochondrial Bioenergetics Function Assessment Method for Traumatic Brain Injury and Polytrauma30 Apr 2026US 2026/0117276 A1The Government of The United States, as represented by The Director of the Defense Health Agency
- Method and system for multiplexed detection of one or more alleles in a sample16 Apr 2026US 2026/0103745 A1Giner, Inc.
- Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (poc) diagnostic testing point-of-care (poc) measurement of absolute neutrophil function (anf)5 Mar 2026US 2026/0063624 A1Binary, LLC
- Diagnosis and/or treatment of heart failure with preserved ejection fraction11 Sep 2025US 2025/0281485 A1Academisch Ziekenhuis Maastricht
Most cited
By later US patents
- Treatment for multiple sclerosis82US 8,399,514 B2Biogen Idec MA Inc. · 2013
- Genetically engineered cell line for detecting infectious herpes simplex virus and method therefore29US 5,418,132 AWashington University · 1995
- Compounds, methods, complexes, apparatuses and uses relating to stabile forms of NAD/NADH29US 7,553,615 B2Roche Diagnostics Operations, Inc. · 2009
- Methods and reagents for analyzing protein-protein interfaces24US 9,989,535 B2Warp Drive Bio, Inc. · 2018
- Methods and reagents for analyzing protein-protein interfaces23US 10,466,249 B2Revolution Medicines, Inc. · 2019